氟哌噻吨美利曲辛联合普瑞巴林治疗痛性糖尿病周围神经病变的临床观察 点击下载
| 论文标题： | 氟哌噻吨美利曲辛联合普瑞巴林治疗痛性糖尿病周围神经病变的临床观察 |
| 英文标题： | |
| 中文摘要： | 目的：观察氟哌噻吨美利曲辛联合普瑞巴林治疗痛性糖尿病周围神经病变（PDPN）患者的疗效及安全性。方法：选取被确诊为PDPN的患者150例，按随机数字表法分为对照A组、对照B组及联合组，各50例。3组患者均予以控制血糖、血压、血脂等常规治疗，对照A组患者在常规治疗上给予甲钴胺注射液1 mg加入0.9％氯化钠溶液250 ml，qd，ivgtt，2周后口服甲钴胺片0.5 mg，tid；对照B组患者在常规治疗上口服普瑞巴林75 mg，bid；联合组患者在对照B组的基础上口服氟哌噻吨美利曲辛片10 mg，bid。3组患者均连续治疗4周。治疗后，比较3组患者疼痛视觉模拟（VAS）评分、汉密尔顿抑郁评分量表（HAMD）评分及正中神经和腓总神经的感觉神经传导速度（SNCV）与运动神经传导速度（MNCV），并观察其临床疗效和不良反应情况。结果：治疗后，联合组患者VAS评分及HAMD评分明显低于对照A组、对照B组，差异有统计学意义（P＜0.05）；联合组患者正中神经和腓总神经的SNCV、MNCV明显高于对照A组、对照B组，差异有统计学意义（P＜0.05）。联合组患者有效率（90.0％）显著高于对照A组（56.0％）和对照B组（74.0％），差异有统计学意义（P＜0.05）。治疗过程中3组患者均未见严重不良反应发生。结论：氟哌噻吨美利曲辛联合普瑞巴林治疗PDPN患者疗效确切，安全性较好。 |
| 英文摘要： | OBJECTIVE： To observe therapeutic efficacy and safety of flupentixol and melitracen combined with pregabalin in the treatment of painful diabetic peripheral neuropathy （PDPN）. METHODS： 150 cases diagnosed as PDPN were selected and randomly divided into control group A， control group B and combination group， with 50 cases in each group. All patients received basic therapy such as the control of blood glucose， blood pressure and blood lipid. Control group A was additionally given mecobalamine 1 mg added into 0.9％ Sodium chloride solution， qd， ivgtt， 2 weeks later， given Mecobalamine tablet 0.5 mg， po， tid； control group B was additionally given pregabalin 75 mg， po， bid； combination group was additionally given Flupentixol and melitracen tablet， 10 mg， bid， on the basis of control group B. 3 groups were given 4 weeks treatment. After treatment， VAS score， HAMD score， and SNCV and MNVC of median nerve and peroneal nerve were compared among 3 groups. Clinical efficacy and ADR were observed. RESULTS： After treatment， VAS score and HAMD score of combination group were significantly lower than control group A and B， with statistical significance （P＜0.05）. SNCV and MNCV of median nerve and peroneal nerve in combination group were significantly higher than in control group A and B， with statistical significance （P＜0.05）.The effective rate of combination group （90.0％） was significantly higher than that of control group A （56.0％） and B （74.0％）， with statistical significance （P＜0.05）. No serious ADR was found in 3 groups during treatment. CONCLUSIONS： Flupentixol and melitracen combined with pregabalin have definite therapeutic efficacy in the treatment of PDPN with good safety. |
| 期刊： | 2016年第27卷第8期 |
| 作者： | 王彦平 |
| 英文作者： | WANG Yanping |
| 关键字： | 氟哌噻吨美利曲辛；普瑞巴林；糖尿病；周围神经病变 |
| KEYWORDS： | Flupentixol and melitracen； Pregabalin； Diabetes； Peripheral neuropathy |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！